All In Biotech

Drug Trial Radar · NCT00852540

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus

Last checked: Nov 20, 2026Latest source record: Mar 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

410

Actual

Start

Apr 2009

Primary completion

Jul 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Stiefel, a GSK CompanyIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Feb 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA. Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up (7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The primary population is the per-protocol MRSA population. It is anticipated that approximately 500 subjects may be enrolled in order to obtain approximately 105 subjects who have a baseline MRSA infection.

Conditions

  • Skin Infections, Bacterial

Interventions

  • Retpamulin Ointment, 1%Drug

    Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.

  • LinezolidDrug

    Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline PathogenTime frame: 7-9 days post-therapy; Day 12-14 for retapamulin and Day 17-19 for linezolid

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Bentonville, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Paragould, Arkansas

  • GSK Investigational Site

    Bakerfield, California

  • GSK Investigational Site

    Bell Gardens, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Atlantis, Florida

  • GSK Investigational Site

    Bay Pines, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

  • GSK Investigational Site

    Vero Beach, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    South Bend, Indiana

  • GSK Investigational Site

    Overland Park, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Grand Blanc, Michigan

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    Butte, Montana

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Carlisle, Ohio

  • GSK Investigational Site

    Tulsa, Oklahoma

  • GSK Investigational Site

    Corvallis, Oregon

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.